Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (298,810)	$ (664,326)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of contingent consideration	0	464
Depreciation and amortization	3,745	17,335
Stock-based compensation expense	30,509	101,829
Loss (gain) on equity securities	3,135	(28,765)
Excess inventory reserve	7,519	29,712
Other non-cash items	2,890	13,358
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(6,197)	(15,720)
Operating lease right-of-use assets	29,650	22,630
Accounts payable	(7,552)	2,004
Accrued expenses and other liabilities	(39,046)	54,774
Operating lease liabilities	(22,523)	(24,499)
Deferred revenue	0	210
Collaboration research advancement	0	(4,920)
Net cash used in operating activities	(296,680)	(495,914)
Cash flows from investing activities:
Purchase of property, plant and equipment	(8,100)	(12,944)
Purchases of marketable securities	0	(421,416)
Proceeds from maturities of marketable securities	125,095	802,367
Proceeds from sales of marketable securities	30,216	31,318
Proceeds from sale of Durham, North Carolina facility	0	110,300
Purchase of intangible assets	0	(8,000)
Net cash provided by investing activities	147,211	501,625
Cash flows from financing activities:
Proceeds from exercise of stock options and ESPP contributions	3	5,078
Net cash provided by financing activities	54,368	80,060
(Decrease) increase in cash, cash equivalents and restricted cash	(95,101)	85,771
Cash, cash equivalents and restricted cash at beginning of period	206,693	373,728
Cash, cash equivalents and restricted cash at end of period	111,592	459,499
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	66,478	402,461
Restricted cash included in receivables and other current assets	1,565	2,530
Restricted cash included in restricted cash and other non-current assets	43,549	54,508
Total cash, cash equivalents and restricted cash	111,592	459,499
Supplemental cash flow disclosures from investing and financing activities:
Purchases of property, plant and equipment included in accounts payable and accrued expenses	176	732
Offering expenses accrued or in AP	298	0
Right-of-use assets obtained in exchange for operating lease liabilities	229,636	22,049
Reduction of right of use asset and associated lease liability	(2,833)	(9,004)
Issuance of unrestricted stock awards to settle accrued employee compensation	0	14,488
Private Placement
Cash flows from financing activities:
Proceeds from issuance of common stock	0	74,982
Public Offering
Cash flows from financing activities:
Proceeds from issuance of common stock	$ 54,365	$ 0